Main menu

NEW YORK (GenomeWeb) – Australian diagnostics firm SpeeDx has received CE marking for an assay to detect resistant strains of Mycoplasma genitalium, the company announced today.

The ResistancePlus MG assay detects M. genitalium as well as mutations in the bacterium's 23S rRNA that confer resistance to the macrolide drug azithromycin.

"As with the better known STD, gonorrhea, M. genitalium has developed serious treatment challenges because of the recent rise of antibiotic resistance," Colin Denver, SpeeDx's CEO, noted in a statement.

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.